Treatment plan for children with brain ependymoma after surgery
Part of Cancer clinical trials.
This trial tests different follow-up treatments for children with brain ependymoma after their initial surgery. Which treatment you get depends on how much tumor is left (if any) and whether the child can safely receive radiation and chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child is under 22 years old at diagnosis, and the tumor is confirmed as ependymoma in the brain
- After surgery, doctors decide which group fits best based on how much tumor can be seen on scans
- No spread to the spine or cancer cells in fluid on spinal testing (spinal MRI and CSF tests)
- No prior radiation therapy, and no prior chemotherapy (steroid medicine is usually allowed)
- Able to take the study chemotherapy medicines safely, with normal blood, liver, and kidney tests
- No active infection, and no medical issues that make chemotherapy or radiation unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at why ependymoma can resist (be harder to treat) after radiation or treatment. It studies children who are already being followed in specific existing programs, which may help researchers find better treatment approaches in the future.
This early-phase study tests a more precisely targeted type of radiation for children with ependymoma, aiming to treat the brain tumor more accurately. It may help reduce how much healthy tissue gets radiation, and researchers are checking safety and best dosing.
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
This trial tests a combination of two oral drugs (axitinib and metronomic etoposide) for children and young adults whose medulloblastoma or ependymoma has come back or is not responding to standard therapy. The goal is to see if this daily pill treatment can control tumor growth with manageable side effects.
This trial tests a treatment that targets tumor blood-vessel growth to slow or shrink relapsed/progressive brain tumors in children. It may help if standard options are no longer working.
Hear when a new Childhood Ependymoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.